Prelude Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Prelude Therapeutics R&D Spending Growth & History (PRLD)
Prelude Therapeutics's r&d spending was $94.3M for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $94.3M | −$23.7M | −20.08% |
| 2024 | 2024-12-31 | $118.0M | $14.6M | +14.12% |
| 2023 | 2023-12-31 | $103.4M | $10.5M | +11.31% |
| 2022 | 2022-12-31 | $92.9M | $6.1M | +7.04% |
| 2021 | 2021-12-31 | $86.8M | $38.6M | +80.12% |
| 2020 | 2020-12-31 | $48.2M | $23.9M | +98.43% |
| 2019 | 2019-12-31 | $24.3M | — | — |
Prelude Therapeutics quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.1M | −$9.7M | −37.44% |
| Q1 2026 | 2026-03-31 | $13.6M | −$15.2M | −52.80% |
| Q4 2025 | 2025-12-31 | $18.0M | −$13.6M | −43.10% |
| Q3 2025 | 2025-09-30 | $21.7M | −$7.7M | −26.31% |
| Q2 2025 | 2025-06-30 | $25.8M | −$3.7M | −12.62% |
| Q1 2025 | 2025-03-31 | $28.8M | $1.4M | +5.13% |
| Q4 2024 | 2024-12-31 | $31.6M | $1.3M | +4.25% |
| Q3 2024 | 2024-09-30 | $29.5M | $3.2M | +12.17% |
| Q2 2024 | 2024-06-30 | $29.5M | $4.5M | +18.20% |
| Q1 2024 | 2024-03-31 | $27.4M | $5.6M | +25.53% |
| Q4 2023 | 2023-12-31 | $30.3M | $4.5M | +17.25% |
| Q3 2023 | 2023-09-30 | $26.3M | $3.4M | +14.73% |
| Q2 2023 | 2023-06-30 | $25.0M | $3.7M | +17.16% |
| Q1 2023 | 2023-03-31 | $21.8M | −$987,000 | −4.32% |
| Q4 2022 | 2022-12-31 | $25.9M | $691,000 | +2.74% |
| Q3 2022 | 2022-09-30 | $22.9M | $168,000 | +0.74% |
| Q2 2022 | 2022-06-30 | $21.3M | −$1.1M | −4.90% |
| Q1 2022 | 2022-03-31 | $22.8M | $6.4M | +38.56% |
| Q4 2021 | 2021-12-31 | $25.2M | $10.6M | +72.78% |
| Q3 2021 | 2021-09-30 | $22.7M | $7.4M | +48.57% |
| Q2 2021 | 2021-06-30 | $22.4M | $12.6M | +129.22% |
| Q1 2021 | 2021-03-31 | $16.5M | $7.9M | +92.95% |
| Q4 2020 | 2020-12-31 | $14.6M | — | — |
| Q3 2020 | 2020-09-30 | $15.3M | $9.8M | +178.56% |
| Q2 2020 | 2020-06-30 | $9.8M | — | — |
| Q1 2020 | 2020-03-31 | $8.5M | — | — |
| Q3 2019 | 2019-09-30 | $5.5M | — | — |
Prelude Therapeutics r&d spending trends
Over the last five fiscal years, Prelude Therapeutics's r&d spending increased from $48.2M to $94.3M, a change of $46.1M. The latest reported quarter, Q2 2026, shows $16.1M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...